CD8A and neoplasm: In mouse tumor models, Monalizumab (an antibody to NKG2A), which is a humanized antibody vaccine against the NKG2A cell membrane receptor protein (18, 43), functions to enhance the immune activity of NK cells and CD8+ T cells against various tumor cells and also increases the survival time of patients (27, 44, 45).